17α-Alkynyl 3α, 17β-androstanediol non-clinical and clinical pharmacology, pharmacokinetics and metabolism

Investigational New Drugs

Volumn 30, Issue 1, 2012, Pages 59-78

  Ahlem, Clarence ^a   Kennedy, Michael ^a   Page, Theodore ^a   Bell, David ^a   Delorme, Evelyn ^a   Villegas, Sonia ^a   Reading, Chris ^a   White, Steven ^a   Stickney, Dwight ^a   Frincke, James ^a  

^a Harbor Biosciences Inc   (United States)

Author keywords

HE3235; Hormone; Pharmacology; Prostate cancer; Toxicology

Indexed keywords

17ALPHA ALKYNYL 3ALPHA,17BETA ANDROSTANEDIOL; ANDROGEN RECEPTOR; ANTINEOPLASTIC AGENT; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DRUG METABOLITE; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; GLUCOCORTICOID RECEPTOR; HE 3235; HE 3539; HE 3562; PRASTERONE; PROGESTERONE RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CLINICAL PHARMACOLOGY; CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EXPOSURE; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; ELECTROCARDIOGRAPHY; ENZYME INDUCTION; ENZYME INHIBITION; FEMALE; GENOTOXICITY; HYPOKALEMIA; IN VITRO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; RAT; SPECIES COMPARISON; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TOXICITY TESTING;

ADMINISTRATION, ORAL; ANDROSTANOLS; ANDROSTENEDIONE; ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; BIOTRANSFORMATION; CELL LINE, TUMOR; CHROMATOGRAPHY, LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; DEHYDROEPIANDROSTERONE; DOGS; DRUG ADMINISTRATION SCHEDULE; ENZYME INDUCTION; ENZYME INHIBITORS; FEMALE; HUMANS; MACACA FASCICULARIS; MALE; METABOLOMICS; MICE; MICROSOMES, LIVER; PROSTATIC NEOPLASMS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SPECIES SPECIFICITY; TANDEM MASS SPECTROMETRY; TESTOSTERONE; TRANSCRIPTIONAL ACTIVATION; TRANSFECTION;

EID: 84856552657     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-010-9517-0     Document Type: Article

References (30)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ (2007) Cancer statistics, 2007. CA Cancer J Clin 57:43-66 (Pubitemid 46148091)
2. Halabi S, Small EJ, Kantoff PW, Kattan MW, Kaplan EB, Dawson NA, Levine EG, Blumenstein BA, Vogelzang NJ (2003) Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 21:1232-1237 (Pubitemid 46606398)
3. Martin C, Ross M, Chapman KE, Andrew R, Bollina P, Seckl JR, Habib FK (2004) CYP7B generates a selective estrogen receptor beta agonist in human prostate. J Clin Endocrinol Metab 89:2928-2935 (Pubitemid 38766387)
4. Bauman DR, Steckelbroeck S, Peehl DM, Penning TM (2006) Transcript profiling of the androgen signal in normal prostate, benign prostatic hyperplasia, and prostate cancer. Endocrinology 147:5806-5816 (Pubitemid 44833497)
5. Koreckij TD, Trauger RJ, Montgomery RB, Pitts TE, Coleman I, Nguyen H, Reading CL, Nelson PS, Vessella RL, Corey E (2009) HE3235 inhibits growth of castration-resistant prostate cancer. Neoplasia 11:1216-1225
6. Wang T, Villegas S, Huang Y, White SK, Ahlem C, Lu M, Olefsky JM, Reading C, Frincke JM, Alleva D, Flores-Riveros J (2010) Amelioration of glucose intolerance by the synthetic androstene HE3286: Link to inflammatory pathways. J Pharmacol Exp Ther 333:70-80
7. U. S. Department of Health and Human Services FaDA, Center for Drug Evaluation and Research (CDER), Center for Biologics evaluation and Research (CBER), Rockville, MD (2006) FDA guidance for industry, drug interaction studies-study design, data analysis, and implications for dosing and labeling.
8. FDA Guidance for Industry (1997) Genotoxicity testing and data intrepretation for pharmaceuticals intended for human use, Rockville, MD.: U. S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), ICH
9. Ames BN, McCann J, Yamasaki E (1975) Methods for detecting carcinogens and mutagens with the Salmonella/mammalianmicrosome mutagenicity test. Mutat Res 31:347-364
10. Maron DM, Ames BN (1983) Revised methods for the Salmonella mutagenicity test. Mutat Res 113:173-215 (Pubitemid 13120319)
11. Green MH, Muriel WJ (1976) Mutagen testing using TRP+ reversion in Escherichia coli. Mutat Res 38:3-32
12. Venitt S, Parry J (eds) (1984) Mutagenicity testing: A practical approach. Washington, DC, Oxford.
13. Evans HJ (1976) Cytological methods for detecting chemical mutagens. In: Hollaender A (ed) Chemical mutagens, principles and methods for their detection, Vol 4. Plenum Press, New York and London, pp 1-29
14. Galloway SM, Bloom AD, Resnick M, Margolin BH, Nakamura F, Archer P, Zeiger E (1985) Development of a standard protocol for in vitro cytogenetic testing with Chinese hamster ovary cells: Comparison of results for 22 compounds in two laboratories. Environ Mutagen 7:1-51 (Pubitemid 15145899)
15. Heddle JA (1973) A rapid in vivo test for chromosomal damage. Mutat Res 18:187-190
16. Schmid W (1975) The micronucleus test. Mutat Res 31:9-15
17. Hayashi M, Tice RR, MacGregor JT, Anderson D, Blakey DH, Kirsh-Volders M, Oleson FB Jr, Pacchierotti F, Romagna F, Shimada H et al (1994) In vivo rodent erythrocyte micronucleus assay. Mutat Res 312:293-304 (Pubitemid 24187390)
18. Moser VC, McCormick JP, Creason JP, MacPhail RC (1988) Comparison of chlordimeform and carbaryl using a functional observational battery. Fundam Appl Toxicol 11:189-206
19. Moser VC, Ross JF (1996) Training video and reference manual for a functional observational battery. U.S. Environmental Protection Agency, Research Triangle Park, NC
20. Meyer OA, Tilson HA, Byrd WC, Riley MT (1979) A method for the routine assessment of fore- and hindlimb grip strength of rats and mice. Neurobehav Toxicol 1:233-236 (Pubitemid 11204691)
21. Edwards PM, Parker VH (1977) A simple, sensitive, and objective method for early assessment of acrylamide neuropathy in rats. Toxicol Appl Pharmacol 40:589-591 (Pubitemid 8141814)
22. Ankier SI (1974) New hot plate tests to quantify antinociceptive and narcotic antagonist activities. Eur J Pharmacol 27:1-4
23. Penning TM, Burczynski ME, Jez JM, Hung CF, Lin HK, Ma H, Moore M, Palackal N, Ratnam K (2000) Human 3alphahydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldo-keto reductase superfamily: Functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones. Biochem J 351:67-77
24. Mottino AD, Veggi LM, Wood M, Roman JM, Vore M (2003) Biliary secretion of glutathione in estradiol 17beta-D-glucuronideinduced cholestasis. J Pharmacol Exp Ther 307:306-313 (Pubitemid 37151922)
25. Zoller AL, Kersh GJ (2006) Estrogen induces thymic atrophy by eliminating early thymic progenitors and inhibiting proliferation of beta-selected thymocytes. J Immunol 176:7371-7378 (Pubitemid 43849038)
26. Trauger R, Corey E, Bell D,White S, Garsd A, Stickney D, Reading C, Frincke J (2009) Inhibition of androstenediol-dependent LNCaP tumour growth by 17alpha-ethynyl-5alpha-androstane-3alpha, 17beta-diol (HE3235). Br J Cancer 100:1068-1072
27. Hennebert O, Montes M, Favre-Reguillon A, Chermette H, Ferroud C, Morfin R (2009) Epimerase activity of the human 11beta-hydroxysteroid dehydrogenase type 1 on 7-hydroxylated C19-steroids. J Steroid Biochem Mol Biol 114:57-63
28. Yamazaki H, Shimada T (1997) Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys 346:161-169 (Pubitemid 27415307)
29. Weihua Z, Lathe R, Warner M, Gustafsson JA (2002) An endocrine pathway in the prostate, ERbeta, AR, 5alphaandrostane- 3beta, 17beta-diol, and CYP7B1, regulates prostate growth. Proc Natl Acad Sci USA 99:13589-13594 (Pubitemid 35221316)
30. Georgiadis EI, Matzoros C, Aliferis C, Batrinos M (1992) Are adrenal and testicular androgen levels correlated?HormMetab Res 24:488-491